Kailera reports Q2 2026 results, oral IND active, Phase 2b fully enrolled
Kailera says its oral ribupatide IND is active with the FDA and its high-dose Phase 2b injection trial has completed enrollment, with cash runway now guided into mid-2028.
SEC filing